Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.16
ACET's Cash-to-Debt is ranked lower than
86% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. ACET: 0.16 )
Ranked among companies with meaningful Cash-to-Debt only.
ACET' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16  Med: 4.17 Max: 74.08
Current: 0.16
0.16
74.08
Equity-to-Asset 0.39
ACET's Equity-to-Asset is ranked lower than
82% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ACET: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
ACET' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.67 Max: 0.76
Current: 0.39
0.39
0.76
Debt-to-Equity 0.87
ACET's Debt-to-Equity is ranked lower than
82% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. ACET: 0.87 )
Ranked among companies with meaningful Debt-to-Equity only.
ACET' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.06 Max: 0.87
Current: 0.87
0
0.87
Interest Coverage 1.94
ACET's Interest Coverage is ranked lower than
87% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.31 vs. ACET: 1.94 )
Ranked among companies with meaningful Interest Coverage only.
ACET' s Interest Coverage Range Over the Past 10 Years
Min: 1.94  Med: 15.24 Max: 147.43
Current: 1.94
1.94
147.43
Piotroski F-Score: 4
Altman Z-Score: 1.57
Beneish M-Score: -1.99
WACC vs ROIC
7.16%
3.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 4.79
ACET's Operating Margin % is ranked lower than
56% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. ACET: 4.79 )
Ranked among companies with meaningful Operating Margin % only.
ACET' s Operating Margin % Range Over the Past 10 Years
Min: 2.72  Med: 5.83 Max: 10.39
Current: 4.79
2.72
10.39
Net Margin % 1.78
ACET's Net Margin % is ranked lower than
62% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. ACET: 1.78 )
Ranked among companies with meaningful Net Margin % only.
ACET' s Net Margin % Range Over the Past 10 Years
Min: 1.78  Med: 3.79 Max: 6.22
Current: 1.78
1.78
6.22
ROE % 3.12
ACET's ROE % is ranked lower than
57% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. ACET: 3.12 )
Ranked among companies with meaningful ROE % only.
ACET' s ROE % Range Over the Past 10 Years
Min: 3.12  Med: 10.25 Max: 13.73
Current: 3.12
3.12
13.73
ROA % 1.34
ACET's ROA % is ranked lower than
59% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. ACET: 1.34 )
Ranked among companies with meaningful ROA % only.
ACET' s ROA % Range Over the Past 10 Years
Min: 1.34  Med: 6.06 Max: 7.33
Current: 1.34
1.34
7.33
ROC (Joel Greenblatt) % 16.07
ACET's ROC (Joel Greenblatt) % is ranked higher than
58% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. ACET: 16.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACET' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 12.2  Med: 25.97 Max: 38.21
Current: 16.07
12.2
38.21
3-Year Revenue Growth Rate 3.10
ACET's 3-Year Revenue Growth Rate is ranked lower than
65% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. ACET: 3.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACET' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.9  Med: 5.7 Max: 14.9
Current: 3.1
0.9
14.9
3-Year EBITDA Growth Rate -3.20
ACET's 3-Year EBITDA Growth Rate is ranked higher than
65% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. ACET: -3.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACET' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -19.6  Med: 6.2 Max: 44.7
Current: -3.2
-19.6
44.7
3-Year EPS without NRI Growth Rate -30.00
ACET's 3-Year EPS without NRI Growth Rate is ranked higher than
61% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. ACET: -30.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACET' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -30  Med: 6.9 Max: 59.8
Current: -30
-30
59.8
GuruFocus has detected 2 Warning Signs with Aceto Corp $ACET.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACET's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ACET Guru Trades in Q3 2016

Chuck Royce 2,522,555 sh (+107.52%)
Keeley Asset Management Corp 71,750 sh (+50.42%)
Jim Simons Sold Out
Ken Fisher 122,091 sh (-27.26%)
» More
Q4 2016

ACET Guru Trades in Q4 2016

Paul Tudor Jones 15,200 sh (New)
Keeley Asset Management Corp 71,050 sh (-0.98%)
Chuck Royce 1,743,186 sh (-30.90%)
Ken Fisher 70,105 sh (-42.58%)
» More
Q1 2017

ACET Guru Trades in Q1 2017

Ken Fisher 103,850 sh (+48.13%)
Paul Tudor Jones Sold Out
Chuck Royce 146,600 sh (-91.59%)
» More
Q2 2017

ACET Guru Trades in Q2 2017

Ken Fisher 138,018 sh (+32.90%)
Chuck Royce 146,600 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ACET

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Add 32.90%$13.75 - $16.06 $ 10.86-27%138,018
Ken Fisher 2017-03-31 Add 48.13%$14.5 - $22.29 $ 10.86-36%103,850
Keeley Asset Management Corp 2016-12-31 Reduce -0.98%$15.73 - $21.97 $ 10.86-45%71,050
Ken Fisher 2016-12-31 Reduce -42.58%$15.73 - $21.97 $ 10.86-45%70,105
Ken Fisher 2016-09-30 Reduce -27.26%$18.37 - $25.71 $ 10.86-52%122,091
Keeley Asset Management Corp 2016-09-30 Add 50.42%0.02%$18.37 - $25.71 $ 10.86-52%71,750
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:COLL, NAS:RIGL, NAS:PETQ, NAS:TTPH, NAS:SNDX, NAS:NEOS, NAS:TOCA, NAS:TLGT, NAS:DEPO, NAS:DRRX, TSXV:ZOM, NAS:CPRX, OTCPK:OPTI, NAS:ADMP, NAS:ADMS, OTCPK:CURR, OTCPK:CBIS, NAS:AGRX, NAS:KPTI, NAS:CPIX » details
Traded in other countries:AZJ.Germany,
Headquarter Location:USA
Aceto Corp is engaged in the marketing, sells and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, and specialty performance chemicals.

Aceto Corp is engaged in the marketing, sales and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals. Its operations are organized into three segments - Human Health, Pharmaceutical Ingredients and Performance Chemicals. The Human Health segment supply's raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and bio chemicals used in pharmaceutical and nutritional preparations. This segment markets and distributes its generic prescription and over the counter pharmaceutical products to wholesalers; chain drug stores; distributors; mass market merchandisers; and others. The Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates to various generic drug companies. The Performance Chemicals segment provides specialty chemicals, such as antioxidants, photo initiators, catalysts, curatives, brighteners, and adhesion promoters, which make plastics, surface coatings, textiles, fuels, and lubricants; diazos and couplers used in microfilms and blueprints, as well as in the photo tooling of printed circuit boards; and organic intermediates and colorants. Its raw materials are also used in electronic parts and binders. This segment also offers agricultural protection products comprising herbicides, fungicides, and insecticides, which control weed growth and the spread of insects and microorganisms; and sprout inhibitor for potatoes. The Company serves various companies, including small trading and fortune 500 companies in the industrial chemical, agricultural, and human health and pharmaceutical market.

Top Ranked Articles about Aceto Corp

ACETO to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
ACETO Board of Directors Declares Quarterly Cash Dividend
ACETO Corporation Schedules Fourth Quarter & Fiscal 2017 Financial Results News Release and Conference Call
ACETO Subsidiary, Rising Pharmaceuticals, Announces Product Launches
ACETO Subsidiary, Rising Pharmaceuticals, Launches Chlorthalidone Tablets, 25 mg and 50 mg, and Glipizide Extended Release Tablets, 2.5 mg, 5 mg and 10 mg
ACETO Subsidiary, Rising Pharmaceuticals, Launches Atomoxetine Capsules, 10, 18, 25, 40, 60, 80 & 100 mg
ACETO Board of Directors Declares Quarterly Cash Dividend 
ACETO Corporation Schedules Third Quarter Fiscal 2017 Financial Results News Release and Conference Call
ACETO Subsidiary, Rising Pharmaceuticals, Launches Zileuton Extended Release Tablets, 600 mg
ACETO Subsidiary, Rising Pharmaceuticals, Launches Capecitabine Tablets, 150 & 500 mg

PORT WASHINGTON, N.Y., March 28, 2017 (GLOBE NEWSWIRE) -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched Capecitabine Tablets, 150 & 500 mg, an AB-rated generic version of Xeloda® Tablets from Hoffman La Roche.  Capecitabine Tablets, 150 & 500 mg, which are indicated for the treatment of metastatic breast cancer, had U.S. sales of approximately $393 million for the 12 months ending December 2016, according to IMS Health.
ACETO Corporation sells generic prescription products and over-the-counter pharmaceutical products under its Rising label to leading wholesalers, chain drug stores, distributors and mass merchandisers, and the launch of Capecitabine Tablets adds to its significant human pharmaceutical franchise.  Rising Pharmaceuticals has built a commercial portfolio of over 110 products currently in the U.S. market. It also has a development portfolio of more than 80 ANDAs filed with the FDA or pending launch, representing over $10 billion in addressable market value, using recent IMS sales data.   ABOUT ACETO ACETO Corporation, incorporated in 1947 and with offices and operations in 10 countries, is engaged in the development, marketing, sale and distribution of Human Health products (finished dosage form generics and nutraceuticals), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products). FORWARD LOOKING STATEMENTS This news release contains forward-looking statements as that term is defined in the federal securities laws.  The events described in forward-looking statements contained in this news release may not occur.  Generally, these statements relate to our business plans or strategies, projected or anticipated benefits or other consequences of ACETO’s plans or strategies, financing plans, projected or anticipated benefits from acquisitions that ACETO may make, or a projection involving anticipated revenues, earnings or other aspects of ACETO’s operating results or financial position, and the outcome of any contingencies.  Any such forward-looking statements are based on current expectations, estimates and projections of management. ACETO intends for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "project," "plan," "intend," "estimate," and "continue," and their opposites and similar expressions are intended to identify forward-looking statements.  The forward-looking statements contained in this press release include, but are not limited to, statements regarding the Company’s strategic initiatives including selling finished dosage form generic drugs, and statements regarding the prospects for long-term growth.   ACETO cautions you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond ACETO’s control, which may influence the accuracy of the statements and the projections upon which the statements are based.  Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in ACETO’s reports filed with the Securities and Exchange Commission, including, but not limited to, ACETO’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016 and other filings. Copies of these filings are available at www.sec.gov.  Any one or more of these uncertainties, risks and other influences could materially affect ACETO’s results of operations and whether forward-looking statements made by ACETO ultimately prove to be accurate. In addition, periodic high-margin product sales may have a positive material financial impact in a given quarter that may be non-recurring in future quarters, thereby rendering one quarter's performance not useful as a predictor of future quarters' results.  ACETO’s actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements.  ACETO undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.
Investor Relations Contact:
LHA
Jody Burfening
[email protected]
(212) 838-3777

Read more...

Ratios

vs
industry
vs
history
PE Ratio 31.95
ACET's PE Ratio is ranked lower than
54% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.93 vs. ACET: 31.95 )
Ranked among companies with meaningful PE Ratio only.
ACET' s PE Ratio Range Over the Past 10 Years
Min: 8.5  Med: 20.23 Max: 91.83
Current: 31.95
8.5
91.83
Forward PE Ratio 8.03
ACET's Forward PE Ratio is ranked higher than
90% of the 67 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.90 vs. ACET: 8.03 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 31.95
ACET's PE Ratio without NRI is ranked lower than
53% of the 554 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.21 vs. ACET: 31.95 )
Ranked among companies with meaningful PE Ratio without NRI only.
ACET' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.5  Med: 20.23 Max: 91.83
Current: 31.95
8.5
91.83
Price-to-Owner-Earnings 16.17
ACET's Price-to-Owner-Earnings is ranked higher than
73% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.90 vs. ACET: 16.17 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ACET' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.52  Med: 22.83 Max: 179.86
Current: 16.17
7.52
179.86
PB Ratio 0.81
ACET's PB Ratio is ranked higher than
84% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. ACET: 0.81 )
Ranked among companies with meaningful PB Ratio only.
ACET' s PB Ratio Range Over the Past 10 Years
Min: 0.76  Med: 1.52 Max: 3.37
Current: 0.81
0.76
3.37
PS Ratio 0.55
ACET's PS Ratio is ranked higher than
87% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. ACET: 0.55 )
Ranked among companies with meaningful PS Ratio only.
ACET' s PS Ratio Range Over the Past 10 Years
Min: 0.31  Med: 0.63 Max: 1.62
Current: 0.55
0.31
1.62
Price-to-Free-Cash-Flow 9.05
ACET's Price-to-Free-Cash-Flow is ranked higher than
81% of the 208 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.89 vs. ACET: 9.05 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ACET' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.68  Med: 20.27 Max: 543
Current: 9.05
7.68
543
Price-to-Operating-Cash-Flow 7.95
ACET's Price-to-Operating-Cash-Flow is ranked higher than
78% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.02 vs. ACET: 7.95 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ACET' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.09  Med: 16.26 Max: 217.3
Current: 7.95
6.09
217.3
EV-to-EBIT 18.80
ACET's EV-to-EBIT is ranked lower than
52% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. ACET: 18.80 )
Ranked among companies with meaningful EV-to-EBIT only.
ACET' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.2  Med: 11.5 Max: 45.7
Current: 18.8
4.2
45.7
EV-to-EBITDA 10.95
ACET's EV-to-EBITDA is ranked higher than
61% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. ACET: 10.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACET' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 9.8 Max: 22.2
Current: 10.95
4
22.2
EV-to-Revenue 0.97
ACET's EV-to-Revenue is ranked higher than
81% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. ACET: 0.97 )
Ranked among companies with meaningful EV-to-Revenue only.
ACET' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.3  Med: 0.6 Max: 1.8
Current: 0.97
0.3
1.8
PEG Ratio 3.30
ACET's PEG Ratio is ranked higher than
65% of the 313 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. ACET: 3.30 )
Ranked among companies with meaningful PEG Ratio only.
ACET' s PEG Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.38 Max: 159.54
Current: 3.3
0.35
159.54
Shiller PE Ratio 15.53
ACET's Shiller PE Ratio is ranked higher than
78% of the 198 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.37 vs. ACET: 15.53 )
Ranked among companies with meaningful Shiller PE Ratio only.
ACET' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.39  Med: 21.51 Max: 47.52
Current: 15.53
11.39
47.52
Current Ratio 2.13
ACET's Current Ratio is ranked lower than
56% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. ACET: 2.13 )
Ranked among companies with meaningful Current Ratio only.
ACET' s Current Ratio Range Over the Past 10 Years
Min: 2.13  Med: 3.03 Max: 3.88
Current: 2.13
2.13
3.88
Quick Ratio 1.52
ACET's Quick Ratio is ranked lower than
60% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. ACET: 1.52 )
Ranked among companies with meaningful Quick Ratio only.
ACET' s Quick Ratio Range Over the Past 10 Years
Min: 1.46  Med: 1.82 Max: 2.61
Current: 1.52
1.46
2.61
Days Inventory 91.49
ACET's Days Inventory is ranked higher than
61% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. ACET: 91.49 )
Ranked among companies with meaningful Days Inventory only.
ACET' s Days Inventory Range Over the Past 10 Years
Min: 76.62  Med: 83.66 Max: 91.49
Current: 91.49
76.62
91.49
Days Sales Outstanding 151.47
ACET's Days Sales Outstanding is ranked lower than
89% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. ACET: 151.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACET' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.39  Med: 76.39 Max: 151.47
Current: 151.47
61.39
151.47
Days Payable 66.03
ACET's Days Payable is ranked higher than
65% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.96 vs. ACET: 66.03 )
Ranked among companies with meaningful Days Payable only.
ACET' s Days Payable Range Over the Past 10 Years
Min: 34.34  Med: 45.97 Max: 66.03
Current: 66.03
34.34
66.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.39
ACET's Dividend Yield % is ranked higher than
58% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. ACET: 2.39 )
Ranked among companies with meaningful Dividend Yield % only.
ACET' s Dividend Yield % Range Over the Past 10 Years
Min: 0.79  Med: 2.05 Max: 4.01
Current: 2.39
0.79
4.01
Dividend Payout Ratio 0.74
ACET's Dividend Payout Ratio is ranked lower than
69% of the 406 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.33 vs. ACET: 0.74 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ACET' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.2  Med: 0.34 Max: 0.77
Current: 0.74
0.2
0.77
3-Year Dividend Growth Rate 2.70
ACET's 3-Year Dividend Growth Rate is ranked lower than
62% of the 299 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.90 vs. ACET: 2.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ACET' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -50.8  Med: 6.9 Max: 126.4
Current: 2.7
-50.8
126.4
Forward Dividend Yield % 2.40
ACET's Forward Dividend Yield % is ranked higher than
53% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. ACET: 2.40 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.99
ACET's 5-Year Yield-on-Cost % is ranked higher than
53% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. ACET: 2.99 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ACET' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.99  Med: 2.57 Max: 5.02
Current: 2.99
0.99
5.02
3-Year Average Share Buyback Ratio -1.50
ACET's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. ACET: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACET' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.4  Med: -0.7 Max: 6.2
Current: -1.5
-4.4
6.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.71
ACET's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
83% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. ACET: 0.71 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACET' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.54  Med: 0.99 Max: 2.53
Current: 0.71
0.54
2.53
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.31
ACET's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
52% of the 83 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.54 vs. ACET: 2.31 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ACET' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.98  Med: 1.61 Max: 3.29
Current: 2.31
0.98
3.29
Price-to-Median-PS-Value 0.89
ACET's Price-to-Median-PS-Value is ranked lower than
68% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. ACET: 0.89 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACET' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 0.8 Max: 2.09
Current: 0.89
0.48
2.09
Price-to-Peter-Lynch-Fair-Value 3.28
ACET's Price-to-Peter-Lynch-Fair-Value is ranked lower than
71% of the 207 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.62 vs. ACET: 3.28 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ACET' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.7  Med: 1.51 Max: 4.67
Current: 3.28
0.7
4.67
Earnings Yield (Greenblatt) % 5.32
ACET's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ACET: 5.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACET' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.2  Med: 8.7 Max: 23.6
Current: 5.32
2.2
23.6
Forward Rate of Return (Yacktman) % 16.83
ACET's Forward Rate of Return (Yacktman) % is ranked higher than
65% of the 380 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.46 vs. ACET: 16.83 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ACET' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.4  Med: 12.3 Max: 48.8
Current: 16.83
-1.4
48.8

More Statistics

Revenue (TTM) (Mil) $638.32
EPS (TTM) $ 0.34
Beta1.18
Short Percentage of Float8.66%
52-Week Range $10.27 - 22.46
Shares Outstanding (Mil)30.11

Analyst Estimate

Jun18 Jun19 Jun20
Revenue (Mil $) 762 808 812
EPS ($) 1.39 1.40 1.43
EPS without NRI ($) 1.39 1.40 1.43
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.00%
Dividends per Share ($) 0.26 0.26 0.26
» More Articles for ACET

Headlines

Articles On GuruFocus.com
ACETO to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Sep 05 2017 
ACETO Board of Directors Declares Quarterly Cash Dividend Aug 24 2017 
ACETO Corporation Schedules Fourth Quarter & Fiscal 2017 Financial Results News Release and Conferen Aug 11 2017 
ACETO Subsidiary, Rising Pharmaceuticals, Announces Product Launches Jul 21 2017 
ACETO Subsidiary, Rising Pharmaceuticals, Launches Chlorthalidone Tablets, 25 mg and 50 mg, and Glip Jun 20 2017 
ACETO Subsidiary, Rising Pharmaceuticals, Launches Atomoxetine Capsules, 10, 18, 25, 40, 60, 80 & 10 May 31 2017 
ACETO Board of Directors Declares Quarterly Cash Dividend  May 04 2017 
ACETO Corporation Schedules Third Quarter Fiscal 2017 Financial Results News Release and Conference Apr 21 2017 
ACETO Subsidiary, Rising Pharmaceuticals, Launches Zileuton Extended Release Tablets, 600 mg Mar 31 2017 
ACETO Subsidiary, Rising Pharmaceuticals, Launches Capecitabine Tablets, 150 & 500 mg Mar 28 2017 

More From Other Websites
Earnings Review and Free Research Report: Braskem’s Net Income Soared 316% Sep 07 2017
ACETO to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Sep 05 2017
ETFs with exposure to Aceto Corp. : September 1, 2017 Sep 01 2017
Weakness Seen in Aceto Corporation (ACET) Estimates: Should You Stay Away? Aug 31 2017
Aceto Corp. breached its 50 day moving average in a Bearish Manner : ACET-US : August 28, 2017 Aug 28 2017
Edited Transcript of ACET earnings conference call or presentation 25-Aug-17 1:00pm GMT Aug 27 2017
Investor Network: Aceto Corporation to Host Earnings Call Aug 25 2017
Aceto posts 4Q profit Aug 24 2017
ACETO Reports Fiscal 2017 Fourth Quarter and Full Year Results Aug 24 2017
ACETO Board of Directors Declares Quarterly Cash Dividend Aug 24 2017
Zacks.com featured highlights: AppFolio, Columbus McKinnon, Concert Pharmaceuticals, Aceto and... Aug 22 2017
5 Stocks to Bet on New Analyst Coverage Aug 21 2017
ACETO Corporation Schedules Fourth Quarter & Fiscal 2017 Financial Results News Release and... Aug 11 2017
ACETO Subsidiary, Rising Pharmaceuticals, Announces Product Launches Jul 21 2017
ACETO to Present at the Singular Summer Solstice Conference Jul 07 2017
ETFs with exposure to Aceto Corp. : June 15, 2017 Jun 15 2017
Aceto Corp. breached its 50 day moving average in a Bullish Manner : ACET-US : June 12, 2017 Jun 12 2017
Aceto Corp. : ACET-US: Dividend Analysis : June 09th, 2017 (record date) : By the numbers : June 8,... Jun 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}